EntryPoint Capital’s NeoGenomics NEO Stock Holding History

EntryPoint Capital’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-23,176	Closed	-$179K	–	806
2025 Q3	$179K	Sell	23,176 -12,314	-35%	-$86.3K	0.07%	570
2025 Q2	$259K	Buy	+35,490	New	+$286K	0.13%	353
2024 Q3	–	Sell	-4,428	Closed	-$61.4K	–	961
2024 Q2	$61.4K	Buy	+4,428	New	+$62.8K	0.09%	490

Other funds holding NEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

EntryPoint Capital's NEO Position: Q4 2025 in Review

EntryPoint Capital sold out of NeoGenomics (NEO) in Q4 2025, closing a stake of 23,176 shares — an estimated $179K sold.

EntryPoint Capital first reported a position in NEO in Q2 2024 and held it in 3 quarters. The position peaked at $259K in Q2 2025. 256 funds tracked by Wall St. Rank hold NEO as of Q4 2025.

EntryPoint Capital reported no remaining NeoGenomics position as of Q4 2025 after selling out during the quarter.
EntryPoint Capital sold 23,176 NeoGenomics shares in Q4 2025, an estimated $179K.
EntryPoint Capital first reported a position in NeoGenomics in Q2 2024 and held it in 3 quarters.
EntryPoint Capital's NeoGenomics position peaked at $259K in Q2 2025.
256 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2025.

Based on EntryPoint Capital's 13F filing for Q4 2025, filed 12 Feb 2026.